CXCR4 intracellular protein promotes drug resistance and tumorigenic potential by inversely regulating the expression of Death Receptor 5

Chemokine receptor CXCR4 overexpression in solid tumors has been strongly associated with poor prognosis and adverse clinical outcome. However, blockade of CXCL12-CXCR4 signaling axis by inhibitors like Nox-A12, FDA approved CXCR4 inhibitor drug AMD3100 have shown limited clinical success in cancer...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:Cell Death Dis
Κύριοι συγγραφείς: Nengroo, Mushtaq A., Maheshwari, Shrankhla, Singh, Akhilesh, Verma, Ayushi, Arya, Rakesh K., Chaturvedi, Priyank, Saini, Krishan K., Singh, Anup K., Sinha, Abhipsa, Meena, Sanjeev, Gupta, Annapurna, Mishra, Anjali, Sarkar, Jayanta, Datta, Dipak
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: Nature Publishing Group UK 2021
Θέματα:
Article
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8106681/
https://ncbi.nlm.nih.gov/pubmed/33966046
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41419-021-03730-8
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια